GSK Entry Inhibitor Aplaviroc Phase IIb Trials Halted Due To Liver Toxicities
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline is halting Phase IIb studies of its chemokine receptor 5 inhibitor aplaviroc following reports of liver toxicities associated with the investigational HIV entry inhibitor